Nabriva Therapeutics AG (NBRVF)

Nabriva Therapeutics AG is a biopharmaceutical company focused on developing and commercializing anti-infective therapies for serious bacterial infections. Its product portfolio includes SIVEXTRO, an oxazolidinone antibacterial used for acute bacterial skin and skin structure infections, XENLETA for community-acquired bacterial pneumonia, and CONTEPO for complicated urinary tract infections, including acute pyelonephritis. The company was incorporated in 2005, previously operated under the name Nabriva Therapeutics Forschungs GmbH, and adopted the Nabriva Therapeutics plc name in 2007. It is headquartered in Dublin, Ireland. The listed security is an ADR, providing a depositary receipt representation of the underlying issuer on OTC Markets under the symbol NBRV.F.

Jump directly to the stock analysis sections supported by the latest available data.